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Abstract
Sensitive and specific tests for detecting exogenous DNA molecules are useful for infectious disease diagnosis, gene therapy
clinical trial safety, and gene doping surveillance. Taqman real-time PCR using specific sequence probes provides an
effective approach to accurately and quantitatively detect exogenous DNA. However, one of the major challenges in these
analyses is to eliminate false positive signals caused by either non-targeted exogenous or endogenous DNA sequences, or
false negative signals caused by impurities that inhibit PCR. Although multiplex Taqman PCR assays have been applied to
address these problems by adding extra primer-probe sets targeted to endogenous DNA sequences, the differences
between targets can lead to different detection efficiencies. To avoid these complications, a Taqman PCR-based approach
that incorporates an internal threshold control (ITC) has been developed. In this single reaction format, the target sequence
and ITC template are co-amplified by the same primers, but are detected by different probes each with a unique fluorescent
dye. Sample DNA, a prescribed number of ITC template molecules set near the limit of sensitivity, a single pair of primers,
target probe and ITC probe are added to one reaction. Fluorescence emission signals are obtained simultaneously to
determine the cycle thresholds (Ct) for amplification of the target and ITC sequences. The comparison of the target Ct with
the ITC Ct indicates if a sample is a true positive for the target (i.e. Ct less than or equal to the ITC Ct) or negative (i.e. Ct
greater than the ITC Ct). The utility of this approach was demonstrated in a nonhuman primate model of rAAV vector
mediated gene doping in vivo and in human genomic DNA spiked with plasmid DNA.
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Introduction
The availability of simplified and controlled tests for detecting
exogenous DNA molecules is of great demand in infectious disease
diagnosis, evaluating biodistribution of vectors used in legitimate
gene therapy clinical trials, and detection of illicit gene doping.
Real-time PCR can detect specific DNA signals, even at a very low
concentration with reliability and specificity. In addition, real-time
PCR is amenable to automation and remote data collectionfor high
throughput screening. Taqman real-time PCR, using specific
sequence probes, provides an efficient method to detect exogenous
DNA accurately and quantitatively. However, to determine with
confidence if the PCR signal is not a false positive or a false negative
requires multiple controls. In addition, for quantitative determina-
tion of copy number, external copy number standard curves are
required and pose a risk of contaminating the laboratory.
Several viral-based and non-viral based gene transfer systems
are being developed and evaluated in human clinical trials. These
systems have demonstrated the ability to safely and efficiently
deliver therapeutic transgenes to a variety of tissues of animals and
humans, and examples of therapeutic benefit in humans are
increasing [1,2,3,4,5,6,7]. Recombinant adeno-associated viral
(rAAV) vectors and naked plasmid are two such gene transfer
systems capable of gene delivery to skeletal muscle of animals
[8,9,10,11,12] and humans [13,14,15,16]. Recently, as an
alternative to direct injection, regional vascular infusion of vector
to achieve skeletal muscle transduction has been reported for
plasmid DNA [17,18] and for rAAV vectors [19,20].
When developing legitimate gene transfer modalities for gene
therapy and vaccination, the evaluation of the distribution of
vector sequences in pre-clinical animal studies and human clinical
trials is required by regulatory agencies to determine the level of
gene delivery to the target tissue and non-target tissues transduced
collaterally, and to evaluate vector shedding into the environment.
The type of vector, the delivery method, injection schedule, route
of administration, and administrated dose are the main variables
to impact biodistribution and shedding [20,21,22,23,24]. To date,
traditional real-time PCR assays have been used to analyze rAAV
vector distribution after administration in human trials [25] or
animal models [9] [26] [27,28,29]. To control for the presence of
different potential inhibitors for each tissue source (eg. matrix
effects), a common practice is to analyze each sample in duplicate
with one of the duplicates spiked with a known number of copies
of a plasmid harboring the PCR target sequences.
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efficient ways to curtail the illegitimate use of genes or genetic
elements that have the capacity to enhance athletic performance,
also referred to as gene doping [30]. These organizations recognize
that gene doping has the potential to threaten the integrity of sport,
undermine principles of fair play in sport, imposespotential harm to
non-dopingathletes, and involves major healthrisks to athletes [31].
Our previous study demonstrated that rAAV viral vectors can be
detected by standard real-time PCR assays in macaque white blood
cell genomic DNA (gDNA) up to 57 weeks after intramuscular
injection. The sensitivity of these assays was validated to 3 copies in
the presence of 500 ng macaque gDNA [32].
One of the major challenges in standard real-time PCR analysis
is how to eliminate the false negative signals which can be caused
by inhibitors [33] or inefficient PCR conditions. Although
multiplex Taqman PCR assays have been applied in an effort to
address problems of reliability, such as by adding an extra primer-
probe sets targeted to other endogenous DNA sequences
(housekeeping genes), however, the sequence and secondary
structure differences between primers and probe binding sites,
and amplified sequences contribute to different detection efficien-
cies. Competitive PCR methods can be used to quantify DNA
copy number, however, the method is limited by the necessity of
assembling multiple competitive reactions for a single determina-
tion and, most notably, the need for a post-PCR electrophoresis-
based detection and analysis step. In realizing these problems and
difficulties of utilizing real-time PCR to detect exogenous DNA
sequences, different Taqman PCR assays which use internal
controls have been applied in an effort to address problems of
reliability, such as by adding an extra primer-probe set targeted to
other endogenous DNA sequences [34] or exogenous targets
[34,35,36,37,38,39,40,41]. These previous approaches were pri-
marily aimed at controlling sample adequacy, eliminating false
negative results, performed in separate reactions, did not share the
same primers, or preferentially amplified the target.
Here, we describe a simplified real-time PCR format that
controls for false negative results and establishes true positive
results, since the copy number of a positive sample must equal or
surpass the copy number of a synthetic internal control. This
system includes the use of a synthetic internal threshold control
(ITC) template and corresponding ITC probe. Sample DNA, a
prescribed number of ITC template molecules, a single pair of
primers, target probe, and ITC probe are added to one reaction.
Fluorescence emission signals are obtained simultaneously to
determine the cycle thresholds (Ct) for amplification of the target
and ITC sequences. Comparison of the Ct from the ITC and the
Ct of the target is the parameter used to determine if a test sample
is positive or negative for the presence of a homologous or
nonhomologous exogenous DNA sequence.
Materials and Methods
Recombinant human and macaque EPO plasmid
The pShuttle-CAG-hEPO-pA plasmid contains the human
erythropoietin (hEPO) cDNA under the control of the CAG
promoter and the SV40 polyA (pA) sequence. The pSSV9-MD2-
cmEPO rAAV vector plasmid harbors the cmEPO transgene
under the control of the CMV promoter and SV40 pA. The
integrity of the plasmids was verified by complete sequencing.
Ethics Statement
Human whole blood samples were obtained from healthy
donors following institutional-approved protocols from the Eta-
blissement Franc ¸ais du Sang, Nantes, France.
Macaque whole blood samples were obtained from the same
animals used in the studies previously described by Ni et al [32].
Experiments were conducted on 3–5 kg captive-bred cynomolgus
macaques purchased from BioPrim (Baziege, France). Macaques
were housed in an enriched environment (toys, fresh fruits and
vegetables) and were monitored daily for health and welfare. The
Institutional Animal Care and Use Committee of the Pays de
Loire (France) approved the protocol (permit number #2007.6).
The research was conducted at the Boisbonne Centre (ONIRIS,
Nantes) under the authorization #5937C delivered by the
Departmental Direction of Veterinary Services (Loire-Atlantique,
France) and in accordance with the recommendations of the
Weatherall report: ‘‘The use of nonhuman primates in research’’.
In order to avoid any discomfort during and after the
experiments, all procedures were carried out after animal sedation
with 30 mg/kg of Medetomidine (DomitorH, Pfizer) and 7 mg/kg
of Ketamine (ImalgeneH, Merial). Intramuscular injections of
rAAV vectors and blood samplings were classified as mild severity
procedures. Special attention was paid to the health and welfare of
animals during the work, and blood samples were collected
regularly to follow biochemical and hematological parameters. In
particular, creatine phosphokinase levels were monitored in the 4
macaques and all stayed in the normal range before injection and
throughout the protocol after administration of the rAAV vector.
rAAV vector production and administration to macaque
skeletal muscle
The rAAV vector production and its administration to macaque
skeletal muscle was described previously [32]. Briefly, for direct
rAAV IM injections, the total dose was split over one or two pre-
tattooed injection sites along the Tibialis Anterior muscle in a
maximal volume of 600 ml. Mac 3 was injected with 2.5E10 vg/kg
of the rAAV1-MD2-cmEPO vector. Mac 4 was injected with
2.5E11 vg/kg of the rAAV1-MD2-cmEPO vector. Mac 5 was
injected with 5E9 vg/kg of the rAAV8-MD2-cmEPO vector. Mac
6 was injected with 2.5E10 vg/kg of the rAAV8-MD2-cmEPO
vector.
DNA extraction from human and macaque white blood
cells
Human (naı ¨ve) and macaque (naı ¨ve and rAAV transduced)
whole blood was collected and DNA extracted from the white
blood cell (WBC) pellet using the Gentra Puregene kit (cat #
158467) from Qiagen, as previously described [32]. Concentration
and purity of the gDNA was determined using a nano-
spectrophotometer from Implen. Integrity of the DNA was
verified by migration of 3 mg of total DNA on a 0.8% agarose
gel, followed by Ethidium Bromide staining, and for macaque
DNA by real-time PCR of the endogenous macaque e-globin gene
as previously described [32].
ITC assay Development: Primer-Probe design
Primers and probes were designed using ABI Primer Express
3.0 based on the cytomegalovirus (CMV) immediate early
promoter in the pSSV9-MD2-cmEPO plasmid, the human EPO
gene (NC_000007.13), or macaque EPO gene (NC_007860.1).
Because of the constraints of the EPO Exon-Exon junction
sequences and the required Tm, screening of multiple primer-
probes combinations was required. Primer and probe sequences
were screened in silico against the human genome and the macaque
genome (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start).
Primers, probes and ITC templates were quantified using a nano-
spectrophotometer from Implen.
ITC PCR Assay
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cmEPO duplex assay. The cmEPO primer-probe assay
targets the cmEPO Exon2–3 junction, harbored in pSSV9-MD2-
cmEPO plasmid. The ITC
cmEPO duplex assay was designed with
forward primer 59AATGAGAATATCACCGTCCCAGAC39,
reverse primer 59AGCTTCTGAGAGCAGGGCC39, cmEPO
probe 6FAM-AAGAGGATGGAGG TCGG-MGBNFQ and
ITC probe 6VIC-CGGCCATTTTCCA-MGBNFQ. The ITC
probe targets ITC
cmEPO template of two complimentary synthetic
single strand DNAs that were annealed. The sequence of the
forward ITC template sequence is 59GAATGAGAATATCAC-
CGTCCCAGACACCAAAGTTAACTT CTATGCCTGGAA-
GACGGCCATTTTCCAAGCAGGCTGTAGAAGTCTGGC-
AGGGCCTGGCCCTGCTCTCAGAAGCTGACGT39 and the
sequence of the complementary sequence is 59CAGCTTCTG-
AGAGCAGGGCCAGGCCCTGCCAGACTTCTACA GCCT-
GCTTGGAAAATGGCCGTCTTCCAGGCATAGAAGTTA-
ACTTTGGTGTCTGGGACGGTGATATTCTCATTCTGCA.39.
b. ITC
hEPO duplex assay. The hEPO primer-probe assay
targets the hEPO Exon3–4 junction, harbored in pShuttle-CAG-
hEPO-pA plasmid. The ITC
hEPO duplex assay was designed with
forward primer 59TGAATGAGAATATCACTGTCCCAGAC39,
reverse primer 59CTTCCGACAGCAGGGCC39, hEPO probe
6FAM-AAGAGGATG GAGGTCGG-MGBNFQ and ITC probe
VIC-CGGCC ATTTTCCA-MGBNFQ. The ITC probe targets
ITC
hEPO template of two complementary synthetic single strand
DNAs that were annealed. The sequence of the forward ITC
template is 59GTGAATGAGAATATCACTGTCCCAGACAC-
CAAAGTTAACTTC TATGCCTGGAAGACGGCCATTTT-
CCAAGCAGGCTGTAGAAGTCTGGCAGGGCCTGGCCC-
TGCTGTC GGAAGGACGT39 and the sequence of the
complementary ITC sequence is 59CCTTCCGACAGCAGGG-
CCAGGCCCTGCCAGACTTCTACAGC CTGCTTGGAAA-
ATGGCCGTCTTCCAGGCATAGAAGTTAACTTTGGTGT-
CTGGGACAGTGATATTCTC ATTCACTGCA39.
c. ITC
CMV duplex assay. The CMV primer-probe assay
targets the CMV immediate early promoter junction, harbored in
pSSV9-MD2-cmEPO plasmid. The ITC
CMV duplex assay was
designed with forward primer 59AATGGGCGGTAGGCG-
TGTA39, reverse primer 59CGATCTGACGGTTCACTA-
AACG39, CMV probe 6FAM-TGGGAGGT CTATATAAGC–-
MGBNFQ and ITC probe VIC-CG GCCATTTTCCA-
MGBNFQ. The CMV ITC probe targets ITC
CMV template of
two complementary synthesized single strand DNAs that were
annealed. The sequence of the forward ITC template is
59CCGATCTGACGGTTCACTAAACGAGCTCTTGGAAA-
ATGGCCGCCGTAC ACGCCTACCGCCCATTCTGCA39
and the sequence of the complementary sequence is
59GAATGGGCGGTAGGCGTGTACGGCGGCCATTTTCC-
AAGAGCTCGTTTAG TGAA CCGTCAGATCGGACGT39.
Traditional real-time PCR program
Taqman Real-time PCR conditions were optimized with
primers and their corresponding fluorescent probes. The concen-
trations of 250 nM probe and 900 nM primers were found to be
optimal. 500 ng of each DNA sample was amplified in a final
volume of 25 mL containing 16TaqManH Universal PCR Master
Mix (Applied Biosystems cat# 4304437). Amplification was
performed using an ABI StepOnePlus PCR machine with an
initial incubation at 50uC for 2 min, a denaturation at 95uC for
10 min, then 40 cycles of denaturation at 94uC for 15 s and an
annealing/extension step at 60uC for 1 min. During thermal
cycling, emission from each sample was recorded and ABI
StepOne software v2.0 processed the raw fluorescence data to
produce threshold cycle (Ct) values for each sample.
ITC duplex assay real-time PCR program
500 ng of macaque gDNA sample (for ITC
cmEPO duplex assay)
or human gDNA (for ITC
hEPO and ITC
CMV duplex assays) was
amplified in a final volume of 30 mL containing 16 TaqManH
Universal PCR Master Mix (Applied Biosystems cat# 4304437) or
16 TaqManH Fast Virus 1-Step Master Mix with reverse
transcriptase (Applied Biosystems cat# 4444432). 5 copies or 10
copies of the corresponding ITC template were added in each
reaction system. DMSO (Sigma D2650) was added in the final
master mix to increase the assay sensitivity. Amplification was
performed using an ABI StepOnePlus PCR machine with an
initial incubation at 50uC for 2 min, a denaturation at 95uC for
10 min, then 40 cycles of denaturation at 94uC for 15 s and an
annealing/extension step at 60uC for 1 min. During thermal
cycling, 6FAM and VIC fluorescence emissions were recorded and
ABI StepOne software v2.0 processed the raw 6FAM fluorescence
data to produce threshold cycle (Ct) values for testing samples and
VIC fluorescence data for ITC templates.
Statistical Analyses
a. SAS Analyses. SAS 9.2 software was utilized to analyze
data from ITC assays. SAS T-Test procedure was applied to
compare the Ct values from each ITC assays. SAS GLM
procedure was used to perform One-Way ANOVA and Two-
Way ANOVA analyses.
b. Equivalence Testing. Independent sample equivalence
testing was performed [42]. The null hypothesis (H0)i s
CtTarget.CtITC and CtTarget,CtITC; The alternative hypothesis
(HA)i sC t Target=Ct ITC. The tolerance limit (D) was set to 0.5 Ct to
evaluate the parity of the Ct’s from the two different real-time
PCR reactions in the duplex assay. The confidence level (a) was set
to 0.10. The critical t-value is ta, 2*n22 which is obtained from the
Student’s t-test distribution table. The observed t-values are
calculated:
tci~
d{({D)
Sd
tcs~
D{d
Sd
d is the difference in the mean Ct between the target sequence and
corresponding ITC template. Sd is the pooled standard deviation
of the two independent samples:
sd~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(n{1)s2
1z(n{1)s2
2
(2n{2)
s

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2n
(n  n)
s
n: Number of replicates
S1: Standard deviation of Cttarget.
S2: Standard deviation of CtITC.
The rejection rule is: if tci and tcs.t a, 2*n22, then reject H0.
Results
A novel real-time PCR-based approach for detecting exogenous
DNA sequences has been developed. The system includes the use
of an internal threshold control (ITC) template and corresponding
ITC probe. The implementation of the ITC involves maintaining
the melting temperature (Tm) of the ITC probe similar to the Tm
of the probe used for the target, having the distance between the
ITC PCR Assay
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distance in the target, and labeling the ITC probe with a
fluorescent dye different than the target probe. In this duplex assay
format, the target and ITC template are co-amplified by the same
primers, but are detected by two different probes each with a
different fluorescent dye. Sample DNA, a prescribed number of
ITC template molecules set near the limit of sensitivity, target
primers, target probe and ITC probe are amplified in one
reaction. Fluorescence emission signals are obtained by the real-
time PCR machine simultaneously to determine the cycle
thresholds (Ct) for amplification of the target and ITC sequences.
Comparison of Ct from the ITC and Ct of the target is the
parameter used to determine if test samples are positive or
negative for the targeted DNA sequence. For the ITC duplex
assays, if the Ct of the target probe is less than or equal to the Ct of
the ITC probe, then the sample is considered a true positive
(meaning that there is the same or more copies of the sequence of
interest relative to the ITC template). Additionally, if the Ct of the
Target probe is greater than the Ct of the ITC probe, then the
sample is considered negative.
Figure 1 represents the features and rationale of applying the
ITC to detect non-endogenous sequences that are either
homologous or non-homologous with genomic DNA. Two
different ITC
EPO duplex assays were developed that target
macaque or human EPO cDNA. These ITC
EPO duplex assays
are performed in the presence of the endogenous homologous
genomic locus, thus the ITC assay needs to distinguish the cDNA
carried in a gene transfer vector from the cellular host genomic
DNA. For this, the EPO primer-probe assays were designed to
target an EPO Exon-Exon junction (Exon 2–3 junction for
cmEPO and Exon 3–4 junction for hEPO). The synthetic ITC
EPO
template includes a different probe binding site and maintains the
flanking EPO sequences including the EPO primer binding sites.
As a consequence, the EPO primers recognize the EPO cDNA in
the viral vector, along with the ITC
EPO template, and macaque or
human gDNA. However, the EPO probe (6FAM dye) specifically
detects the EPO cDNA, and the EPO ITC probe (VIC dye)
specifically detects the EPO ITC template and neither can detect
genomic DNA (Figure 1A).
To demonstrate the applicability of the ITC duplex assay
approach to address infectious agent detection, we also developed
an ITC duplex assay in which the cytomegalovirus (CMV)
promoter, used in the pSSV9-MD2-cmEPO plasmid, was
targeted. The CMV promoter PCR target developed here is
homologous to the promoter found in most CMV strains,
including: the Towne strain (Genbank AY315197) that is the
basis of the National Institute of Standards and Technology
(NIST) Reference plasmid, the Merlin strain (Genbank
Figure 1. Internal Threshold Control (ITC) assay format. Panel (A) ITC
EPO duplex assay format. The EPO probe specifically detects the EPO
cDNA harbored in rAAV vectors and does not bind to the genomic DNA because it rests on an exon/exon junction. The EPO ITC probe recognizes
only the synthetic ITC
EPO template. The EPO primers recognize the EPO cDNA, the ITC
EPO template, and the genomic EPO locus. Panel (B) ITC
CMV
duplex assay format. The CMV probe specifically detects the CMV immediate early promoter region in the pSSV9-MD2-cmEPO plasmid. The CMV ITC
probe recognizes only the synthetic ITC
CMV template. The CMV primers recognize the CMV promoter and the ITC
CMV template.
doi:10.1371/journal.pone.0036461.g001
ITC PCR Assay
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reference standard (National Institute for Biological Standards and
Control (NIBSC) product # 09/162), the JP strain (Genbank
GQ221975) from a clinical specimen, and cell culture strains
HAN38 (Genbank GQ396662) and VR1814 (Genbank
GU179289). Since the heterologous CMV sequences are targeted,
there is no competition with the host genomic DNA (Figure 1B).
Traditional real-time PCR assays to detect the hEPO cDNA
and CMV promoter were first developed using an approach
similar to our previously published assay for cmEPO cDNA [32].
Design of the corresponding synthetic ITC template for each of
these targets requires that (1) the distance between the primers is
similar to the distance between the same primer sites on the target;
(2) the target probe and ITC probe have similar Tm; (3) the PCR
products have similar Tm; (4) there is no homology between the
target probe and ITC template nor between ITC probe and target
sequences. For each assay the primers and probes were verified in
silico to ensure that there was no cross hybridization between
primers, primers and probes, primers/probe sets and EPO cDNA
or genomic DNA or ITC template. The PCR products of each
individual PCR assay were analyzed by agarose gel electrophoresis
and demonstrated a single band (data not shown). The
performance of each individual assay was evaluated.
Performance and detection limits of individual assays
Traditional real-time PCR was performed to evaluate the lower
limit of quantitation and linearity of the six individual assays. A
titration of the pSSV9-MD2-cmEpo plasmid in the presence of
naı ¨ve macaque genomic DNA illustrates that the cmEPO assay is
capable of detecting 5 copies. Likewise, a titration of the
ITC
cmEPO template illustrates that the ITC
cmEPO assay is capable
of detecting 5 copies in the presence of naı ¨ve macaque genomic
DNA. The sensitivities of the individual hEPO, ITC
hEPO, CMV,
ITC
CMV assays in the presence of naı ¨ve human genomic DNA is
10 copies. The linearity of all the six assays is above 0.98 over an 8
log dynamic range from 10 to 1E9 copies (Table 1). The
reduction in efficiencies seen in the presence of gDNA most likely
reflects competition for primers. To evaluate the accuracy of
detecting the sequences at the lower limit of quantitation, 15
replicates were performed for cmEPO and ITC
cmEPO assays at 5
copies and at 10 copies for the other four assays and the means
and standard errors of copy number and Ct were calculated
(Table 2).
Specificity of the individual assays
The specificity of the individual assays was tested (Table 3). A
lack of signal at 40 cycles was defined as ‘‘negative’’ and a Ct signal
Table 1. Individual assay linearity and efficiency.
Assay Linearity (R
2) Linearity (R
2) Efficiency (%) Efficiency (%)
in the absence of 500 ng
gDNA
in the presence of 500 ng
gDNA*
in the absence of 500 ng
gDNA
in the presence of 500 ng
gDNA
cmEPO 0.992 0.989 95 82
ITC
cmEPO 0.989 0.998 91 86
hEPO 0.999 0.998 92 88
ITC
hEPO 0.996 0.993 89 86
CMV 0.996 1.000 99 97
ITC
CMV 0.997 0.989 98 94
*macaque gDNA with cmEPO and ITC
cmEPO assays, and human gDNA with hEPO, ITC
hEPO, CMV and ITC
CMV assays.
doi:10.1371/journal.pone.0036461.t001
Table 2. Individual assay sensitivity.
Assay Positive Control Mean* Copy Number (s.e.) Mean* Ct (s.e.) CV (%) of Ct
cmEPO 5 copies pDNA with 500 ng gDNA (macaque) 6.7 (2.5) 37.24 (0.22) 2.2
5 copies pDNA with TE 5.9 (3.4) 37.47 (0.28) 2.9
ITC
cmEPO 5 copies ITC template with 500 ng gDNA (macaque) 6.5 (2.7) 37.22 (0.24) 1.5
5 copies ITC template with TE 5.5 (3.8) 37.14 (0.31) 3.2
hEPO 10 copies pDNA with 500 ng gDNA (human) 9.6 (3.3) 36.74 (0.14) 1.5
10 copies pDNA with TE 10.8 (2.8) 36.45 (0.10) 1.1
ITC
hEPO 10 copies ITC template with 500 ng gDNA (human) 11.8 (3.9) 36.55 (0.14) 1.6
10 copies ITC template with TE 11.1 (2.4) 36.73 (0.10) 0.9
CMV 10 copies pDNA with 500 ng gDNA (human) 11.9 (5.3) 36.29 (0.18) 2.0
10 copies pDNA with TE 11.1 (4.1) 36.35 (0.14) 1.5
ITC
CMV 10 copies ITC template with 500 ng gDNA (human) 10.7 (4.3) 36.64 (0.16) 1.7
10 copies ITC template with TE 11.8 (4.0) 36.55 (0.13) 1.4
*From fifteen replicates of plasmid (pDNA) or ITC template. Standard error, s.e., (in parenthesis).
doi:10.1371/journal.pone.0036461.t002
ITC PCR Assay
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500 ng of naı ¨ve macaque or human gDNA were used as samples.
Table 3 demonstrates that no false positive signals were detected
in 20 replicates of each of the six individual assays caused by either
non-targeted exogenous or endogenous DNA sequences, or
laboratory contamination. To confirm that we are detecting the
vector genome harboring the EPO cDNA and not residual
endogenous mRNA, we obtained the copy number signal with our
standard master mix and this signal was not influenced by RNase.
Furthermore, when a master mix that utilizes a reverse
transcriptase step was used, endogenous mRNA was detected
and this RT-dependent signal was reduced with an RNase A pre-
treatment (data not shown).
Equivalence testing of ITC duplex assays
Each of the three individual target assays was paired with the
corresponding ITC assay to create the three ITC duplex assays.
The ITC duplex assay format includes the requirement that same
copy number of target sequences and corresponding ITC
templates give similar Ct’s. In cases where the P-value shows a
statistically significant difference, such as when the Ct of the target
is significantly higher or lower than the Ct of the ITC, then the
Student’s t-test can be used. However, when the Ct of the target is
equal to the Ct of the ITC, the equivalency needs to be confirmed
statistically to be able to designate the sample as a true positive.
Equivalence testing of our three ITC duplex assays was
performed. Each assay was used to detect target DNA sequences
near their limit of sensitivity in the presence of an equal amount of
ITC template and 500 ng of naı ¨ve gDNA (Figure 2). Fifteen
replicates were performed and the Ct’s were recorded and
analyzed. First, large P-values (cmEPO P=0.5816, hEPO
P=0.6783, CMV P=0.4819) were obtained by the Student’s t-
test suggesting that no significant differences exist between each
target Ct and the corresponding ITC Ct from all three duplex
assays. To determine if the Ct values were statistically equivalent,
equivalence testing was conducted (see Materials and Methods),
where the tolerance limit was set as 0.5 Ct (equal to 1.5% of the
max Ct of 37), the confidence level (a) was set to 0.10, and the
critical t-value is t0.10, 28=1.31. The calculated tci, and tcs of the
three assays are 2.8 and 1.7 for cmEPO, 2.7 and 2.1 for hEPO,
and 1.6 and 3.0 for CMV. All of these t-values are greater than the
critical t-value of 1.31, demonstrating that the Ct from a target
DNA and the Ct from an equal amount of corresponding ITC
template in each duplex assay are statistically equivalent.
Assay Precision
As shown in Table 2, the reproducibility of the assays was
evaluated. Coefficients of variation (CV) from all six assays are
within 3.2%. Furthermore, to determine the precision of the
ITC
hEPO duplex assay, an additional experiment was conducted
where eight replicates of the ITC
hEPO duplex assay were
Table 3. Individual assay specificity.
Assay Negative Control
False
positive
False Positive
Rate (%)
cmEPO 500 ng gDNA (macaque) 0/20 0
ITC
cmEPO 500 ng gDNA (macaque) 0/20 0
hEPO 500 ng gDNA (human) 0/20 0
ITC
hEPO 500 ng gDNA (human) 0/20 0
CMV 500 ng gDNA (human) 0/20 0
ITC
CMV 500 ng gDNA (human) 0/20 0
doi:10.1371/journal.pone.0036461.t003
Figure 2. ITC duplex assay equivalence testing. All three ITC duplex assays were tested in the presence of same amount of target and ITC
template and 500 ng naı ¨ve gDNA. Five copies of pSSV9-MD2-cmEPO plasmid and ITC
cmEPO template were amplified using the ITC
cmEPO duplex assay.
10 copies of pShuttle-CAG-hEPO-pA plasmid and ITC
hEPO template were amplified using the ITC
hEPO duplex assay. 10 copies of pSSV9-MD2-cmEPO
plasmid and ITC
CMV template were amplified using the ITC
CMV duplex assay. Each reaction was repeated 15 times. Similarities in mean Ct values were
analyzed statistically as described in Materials and Methods.
doi:10.1371/journal.pone.0036461.g002
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the presence of naı ¨ve human gDNA. The intra-assay CV is 1.3%
and the inter-assay CV is 2.8%. These CVs of less than 3%
demonstrate that the ITC
hEPO assay is highly reproducible.
Moreover, one-way ANOVA was performed to determine the
relationship between testing days and Ct from the individual
hEPO and ITC
hEPO PCR reactions, and shows that each Ct does
not vary significantly over the testing days (data not shown).
Evaluation of assay interference
The target probe and its corresponding ITC probe are designed
to detect two unique DNA sequences in one reaction. However,
the two amplification systems share the same pair of primers, thus,
possible competition between the target PCR reaction and the
ITC PCR reaction was analyzed for each of the three ITC duplex
assays. Experiments were performed where the copy number of
the ITC template was held at 5 copies (cmEPO ITC) or 10 copies
(hEPO or CMV ITC) in each reaction, while the target template
was titrated from 5 or 10 copies to 100 copies, which is at the
upper range of rAAV copies seen in 500 ng of macaque WBC
gDNA at late timepoints following intramuscular injection [32]. As
shown in Figure 3, the observed Ct from the ITC probe is stable
while the Ct from the corresponding target probe increases
according to the decrease in target copy number in the presence of
500 ng naı ¨ve gDNA. All three assays show the same pattern,
which demonstrates that the target template does not interfere
Figure 3. ITC duplex assay competition testing. The copy number of the ITC template was held at 5 copies (cmEPO ITC) or 10 copies (hEPO or
CMV ITC) in each reaction, while the target template was titrated from 5 or 10 copies to 100 copies. Each reaction was repeated 5 times in the
presence of 500 ng naı ¨ve gDNA to obtain the mean Ct value. Panel (A) ITC
cmEPO duplex assay, Panel (B) ITC
hEPO duplex assay and Panel (C) ITC
CMV
duplex assay.
doi:10.1371/journal.pone.0036461.g003
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where the target copy number is over 100 copies, then an
unequivocal signal will be detected by the target probe, even if an
ITC signal is not detected, and will warrant further analysis of the
sample.
In addition, testing was performed to evaluate the dynamic range
of all the three ITC duplex assays (Figure 4). The total number of
the two templates was maintained at 100 copies. For each duplex
assay, a plasmid harboring the target was titrated reciprocally with
the ITC template in the presence of 500 ng naı ¨ve gDNA. The Ct of
both probes illustrates that the Ct values for each template changed
only with the template amount, without interference from the other
template. As a result, if no signal is obtained from the ITC template
itis most likelyduetoan inhibitorpresentinthesample, andthetest
will be invalid and require further analysis.
Transduced Macaque blood sample testing
The performance of the ITC assay format was evaluated on the
WBC DNA samples taken from macaques transduced in vivo with
rAAV vectors and previously analyzed by traditional real-time
PCR, where the actual copy number was determined at each
timepoint [32]. The ITC
cmEPO duplex assay was conducted on
both rAAV1 and rAAV8 in vivo samples. For the ITC testing, a
500 ng DNA sample and 5 copies of ITC
cmEPO template were
amplified simultaneously in the presence of the cmEPO primers,
the cmEPO probe, and the cmEPO ITC probe, and both
fluorescence signals were recorded to obtain the Ct’s. Each sample
was tested repeatedly 5 times in order to acquire the mean and
standard error for statistical analysis. Comparing the mean of
cmEPO Ct and ITC
cmEpo Ct, the tested samples are defined to be
positive (cmEPO Ct is less than or equal to the ITC
cmEpo Ct) or
negative (cmEPO Ct is greater than ITC
cmEpo Ct with P-
Value,0.05). As shown in Table 4, the ITC
cmEPO duplex assay
results from both rAAV1 and rAAV8 injected animals are
consistent with the previous absolute copy number data. Samples
having more than two copies per 500 ng DNA are positive in the
ITC duplex assay, meanwhile, the pre-injected samples test
negative. The Student’s t-test was applied and P-values of
Figure 4. ITC duplex assay interference testing. Target plasmid (¤) and ITC template (O) were amplified in one reaction in the presence of
500 ng naı ¨ve gDNA to test the influence on the Ct between the two DNA targets. The total copy number of the plasmid and ITC template was
maintained at 100. The target plasmid copy number is 10, 25, 50, 75, 90 and the ITC template copy number is 90, 75, 50, 25, 10 from left to right. Each
reaction was repeated 5 times to obtain the mean Ct value. Panel (A) ITC
cmEPO duplex assay Panel (B) ITC
hEPO duplex assay and Panel (C) ITC
CMV
duplex assay.
doi:10.1371/journal.pone.0036461.g004
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between cmEPO cDNA and ITC
cmEPO template copy numbers is
larger than five, demonstrating that this Ct difference is statistically
significant. In addition, there is little to no competition of the
target with the ITC, since the Ct’s of the ITC for both animals at
all vector copy numbers is ,37 (CV=1.5%). Furthermore, the
samples do not appear to contain inhibitors since the Ct=37 is
similar to the Ct seen in TE (in the absence of gDNA, Table 2).
Testing of human WBC gDNA spiked with plasmid DNA
The plasmid pShuttle-CAG-hEPO-pA harboring the hEPO
cDNA was spiked into 500 ng naı ¨ve human gDNA at the same
copy numbers detected in the rAAV1 injected macaque shown in
Table 4, and ten copies of ITC
hEPO template was added to each
reaction. Table 5 shows that spiking with 188, 13 and 8 copies of
pShuttle-CAG-hEPO-pA were designated as positive, meanwhile
0 and 2 copies were designated negative when compared to the
ITC
hEPO Ct.
The ITC duplex assay format is also capable of being used to
detect human infectious agents such as viruses or bacteria that
have sequences that are non-homologous to human genomic
DNA. Cytomegalovirus causes many human infections [43], and
the viral load in blood is very important for clinicians to evaluate
patients’ prognosis. As a proof of concept, The CMV immediate
early promoter in plasmid pSSV9-MD2-cmEPO was used as a
PCR target for two reasons. The first is to compare the sensitivity
of the EPO intron-spanning PCR to a target that has no
competition with human genomic DNA, and the second is to
demonstrate the applicability to using the ITC approach for
infectious disease diagnosis and treatment monitoring. As can be
seen in Tables 1 and 2, the CMV and hEPO assays had similar
10 copy sensitivities.
For the ITC
hEPO and ITC
CMV duplex assays, we determined
the difference in the Ct’s between the target sequence and
corresponding ITC template at the 95% confidence interval. For
this purpose, the ITC templates were held constant at 10 copies
and a titration of 5, 10 and 20 copies of target plasmid were added
to evaluate the ability to determine positive (10 and 20 copies)
from negative (5 copies) samples. Four different naı ¨ve human
gDNA samples spiked with 5, 10 and 20 copies of hEPO or CMV
target plasmid were amplified in the presence of 10 copies of their
corresponding ITC template. The Ct’s were analyzed by Student’s
Table 4. ITC
cmEPO duplex assay testing of WBC samples from NHP transduced IM in vivo with rAAV1 or rAAV8.
Serotype/Time Point Mean* cmEPO Ct (s.e.) Mean ITC
cmEPO Ct** (s.e.) Positive/Negative Actual Copy Number***
rAAV1/Pre-injection. 40.00
# (0) 37.00 (0.29) Negative (P-value,0.0001) 0
rAAV1/3 Days p.i. 32.81 (0.10) 37.21 (0.15) Positive (P-value,0.0001) 188
rAAV1/7 Days p.i. 35.92 (0.27) 37.48 (0.29) Positive (P-value=0.0019) 13
rAAV1/14 Days p.i. 36.94 (0.51) 37.46 (0.40) Positive (P-value=0.4350) 8
rAAV1/10 Weeks p.i. 38.49 (0.49) 37.67 (0.13) Positive (P-value=0.1066) 2
rAAV1/16 Weeks p.i. 38.32 (0.72) 37.16 (0.73) Positive (P-value=0.2913) 3
rAAV1/23 Weeks p.i. 39.91 (0.09) 37.18 (0.23) Negative (P-value,0.0010) 0
rAAV8/Pre-injection. 40.00
# (0) 37.43 (0.24) Negative (P-value,0.0001) 0
rAAV8/3 Days p.i. 35.70 (0.49) 36.67 (0.12) Positive (P-value,0.0875) 10
rAAV8/7 Days p.i. 36.68 (0.35) 36.99 (0.44) Positive (P-value=0.5923) 7
rAAV8/14 Days p.i. 37.44 (0.43) 37.43 (0.14) Positive (P-value=0.9795) 8
rAAV8/10 Weeks p.i. 40.00 (0) 36.82 (0.33) Negative (P-value,0.0001) 0
rAAV8/16 Weeks p.i. 38.02 (0.68) 36.83 (0.68) Positive (P-value=0.2528) 2
rAAV8/23 Weeks p.i. 38.17 (0.54) 37.30 (0.19) Positive (P-value=0.1432) 3
*From five replicates of each 500 ng in vivo sample. s.e.=standard error, s.e., (in parenthesis).
**From an input of five copies of ITC
cmEPO template.
***The actual copy number is from our previous study [32].
#The number of cycles of the real-time PCR program was set to 40.
doi:10.1371/journal.pone.0036461.t004
Table 5. ITC
hEPO duplex assay testing.
Copy Number of Spiked Plasmid Mean* hEPO Ct (s.e.) Mean ITC
hEPO Ct** (s.e.) Positive/Negative
04 0 . 0 0
# (0) 36.93 (0.42) Negative (P-value,0.0001)
188 32.60 (0.44) 36.48 (0.33) Positive (P-value,0.0001)
13 36.63 (0.28) 37.12 (0.27) Positive (P-value=0.2426)
8 36.88 (0.28) 36.84 (0.28) Positive (P-value=0.9172)
2 39.80 (0.20) 37.32 (0.37) Negative (P-value,0.0001)
*From five replicates of pShuttle-CAG-hEPO-pA plasmid DNA spiked into 500 ng naı ¨ve human gDNA. Standard error, s.e., (in parenthesis).
**From an input of 10 copies of ITC
hEPO template.
#The number of cycles of the real-time PCR program was set to 40.
doi:10.1371/journal.pone.0036461.t005
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four human gDNA sources, the Ct from 5 copies of hEPO or
CMV target sequence is significantly larger than 10 copies of
corresponding ITC template, the Ct from 20 copies is significantly
smaller than 10 copies of ITC template, and no statistical
difference (evaluated by equivalence testing – data not shown)
was seen when the target and ITC copy numbers were equal at 10
copies each. Two-Way ANOVA analysis was performed and
showed that the copy number detected was independent of the
different gDNA samples (data not shown).
Discussion
We report developing a real-time PCR assay format for
detecting homologous and non-homologous exogenous DNA.
These tests are useful for infectious disease diagnosis, gene therapy
clinical trial safety, and gene doping surveillance where the control
of false negative and false positive results, and the assurance of true
positive results is required. These procedures facilitate the
procurement, preparation, and testing of samples to detect
exogenous DNA sequences in a user-friendly format. Furthermore,
the ITC assay format described here is ideal for clinical testing labs
since 1) it is a ‘‘single tube’’ assay [sample DNA+master mix (2
primers, 2 probes and ITC template)], 2) it is specific and sensitive
with samples internally controlled, 3) it is fast: 2 to 3 hours
(including set up and analysis), 4) it requires no standard curve
titration tubes (no external standards), 5) it is high throughput,
capable of analyzing many samples at once, 6) it is automated:
data captured by PCR machine and results can be transferred to
centralized database(s), 7) no additional manipulations are needed
for analysis such as gel electrophoresis, and 8) it reduces risk of
laboratory contamination (a source of false positives) since no
positive control plasmid is needed and uracil-N-glycosylase (UNG)
prevents the re-amplification of carryover PCR products in
subsequent analyses.
When designing and validating an ITC duplex assay, in
addition to considering GC content, primer and probe Tm, and
amplicon length, additionally, lack of cross complementary of the
primers and two probes, the targets or amplicons, or any
combination of these is needed [44]. Moreover, since both assays
are amplified in a single tube, amplification competes for the same
dNTPs and polymerase. One more challenge in the detection of
cDNAs in the presence of gDNA is that the assay must detect the
exon-exon junction of the cDNA, which greatly restricts the choice
of primers and probes.
The individual assays described here have a sensitivity of 10
copies or better in the presence of 1.5E5 cellular genome copies
and maintain linearity over 8 logs. The two probes in each duplex
assay give similar Ct values when detecting the same amount of
their respective sequences, and this was supported statistically
using equivalence testing. Interference and competition testing has
shown that target probe, ITC probe, target template and ITC
template will not inhibit each other in the range of 10–100 copies.
Furthermore, similar amplification of the PCR targets was
Table 6. Human EPO cDNA detection in the presence of different naı ¨ve human gDNA samples.
Human
gDNA 5:10* 10:10** 20:10***
Mean
1 hEPO Ct
Mean ITC
hEPO
Ct P-Value Mean
1 hEPO Ct
Mean ITC
hEPO
Ct P-Value Mean
1 hEPO Ct
Mean ITC
hEPO
Ct P-Value
1 37.36 (0.84) 36.25 (0.53) 0.0368 36.80 (0.41) 36.70 (0.83) 0.8853 35.36 (0.46) 36.95 (0.50) 0.0482
2 38.03 (0.40) 36.25 (0.24) 0.0052 36.88 (0.32) 36.99 (0.58) 0.8663 35.17 (0.39) 36.41 (0.14) 0.0168
3 37.45 (0.85) 36.39 (0.38) 0.0253 36.94 (0.44) 37.14 (0.83) 0.7840 35.18 (0.44) 37.46 (0.59) 0.0143
4 37.62 (0.33) 36.24 (0.10) 0.0040 36.91 (0.35) 37.00 (0.79) 0.8924 35.34(0.45) 36.97 (0.50) 0.0425
1From five replicates of pShuttle-CAG-hEPO-pA plasmid DNA spiked into 500 ng naı ¨ve human gDNA. Standard error (in parenthesis).
*5 copies of plasmid and 10 copies of ITC template.
**10 copies of plasmid and 10 copies of ITC template.
***20 copies of plasmid and 10 copies of ITC template.
The number of cycles of the real-time PCR program was set to 40.
doi:10.1371/journal.pone.0036461.t006
Table 7. CMV promoter detection in the presence of different naı ¨ve human gDNA samples.
Human
gDNA 5:10* 10:10** 20:10***
Mean
{ CMV Ct Mean ITC
CMV Ct P-Value Mean
{ CMV Ct Mean ITC
CMV Ct P-Value Mean
{ CMV Ct Mean ITC
CMV Ct P-Value
1 38.88 (0.35) 36.27 (0.08) ,0.0001 36.77 (0.08) 36.62 (0.12) 0.3259 36.21 (0.09) 36.65 (0.11) 0.0172
2 38.37 (0.32) 36.70 (0.12) 0.0011 36.56 (0.14) 36.97 (0.15) 0.3333 36.11 (0.11) 36.69 (0.08) 0.0025
3 38.55 (0.42) 36.82 (0.13) 0.0045 36.78 (0.07) 36.74 (0.13) 0.7807 36.23 (0.14) 36.91 (0.13) 0.0081
4 38.83 (0.32) 36.73 (0.18) 0.0005 36.67 (0.12) 36.67 (0.08) 0.9355 36.06 (0.23) 36.71 (0.04) 0.0183
{From five replicates of pSSV9-MD2-cmEPO plasmid DNA spiked into 500 ng naı ¨ve human gDNA. Standard error (in parenthesis).
*5 copies of plasmid and 10 copies of ITC template.
**10 copies of plasmid and 10 copies of ITC template.
***20 copies of plasmid and 10 copies of ITC template.
The number of cycles of the real-time PCR program was set to 40.
doi:10.1371/journal.pone.0036461.t007
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PCR reactions.
The maintenance of rAAV sequences in WBC of nonhuman
primates [32] and humans [25] provides an easily accessible target
for the surveillance of gene doping. Our previous experiments in
the nonhuman primate were designed to test the feasibility of
detecting vector sequences in blood long-term following IM
injection and to gain insight into testing humans. We have
designed the ITC duplex PCR format described in this paper with
the expectation that athlete samples will be sent to testing
laboratories for preparation and PCR analysis, and then the test
results will then be sent to central databases for analysis and
trending. The methods developed to detect EPO also provide the
basis to detect other prohibited gene doping targets.
Previous studies have introduced internal controls using cellular
housekeeping genes to control for possible PCR inhibitory factors,
but they were not used to set a copy number threshold of the
exogenous sequence target [45–46]. Moreover, competitive PCR
methods are used to quantify DNA copy number, however, this
approach is limited by the necessity of assembling multiple
competitive reactions for a single determination and, most notably,
the need for a post-PCR detection and analysis step [47]. On the
other hand, each ITC duplex assay detects two different DNA
sequences in one reaction by real-time PCR, with the Ct from the
ITC probe being a threshold to evaluate if the samples are positive
or negative. The ITC
cmEPO duplex assay testing on blood samples
from macaques transduced in vivo with rAAV vectors shows
consistent results with our previous quantitative data [32].
Furthermore, to simulate the testing of human samples, the ITC
templates were held constant and the corresponding hEPO or
CMV target plasmid was titrated in the presence of naı ¨ve human
genomic DNA to evaluate the ability to determine positive from
negative samples.
ITC assays can be used to detect heterologous sequences
(infectious agents) or exogenously added homologous cDNA
sequences (gene transfer vectors). Thus, ITC assays can be applied
to pre-clinical animal biodustribution studies and legitimate
human gene therapy clinical trials to determine the presence or
absence of gene transfer vector sequences in different tissues,
where the ITC can control for different types of inhibitors
potentially present in different tissue samples. Likewise, molecular
tests for infectious disease diagnosis, prognosis, and evaluation of
response to therapy could benefit from an ITC assay approach.
The ITC assay format is also applicable to gene doping
surveillance testing as a means to deter the illegitimate use of
gene transfer vectors for athletic performance. Compared to
traditional real-time PCR, the ITC assay format has advantages
for detecting exogenous DNA.
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